Repellency by commercial transfluthrin products consists of both Or-mediated and Or-independent repellency in <i>Ae</i>. <i>aegypti</i>. by Felipe Andreazza (11098928)

ALVAC-HIV elicits V2, V3, and CD4 inducible (CD4i) binding antibody responses. by LaTonya D. Williams (3140490)

Delayed boosting with ALVAC-HIV/AIDSVAX B/E or AIDSVAX B/E increases breadth of Env-specific IgG response. by LaTonya D. Williams (3140490)

Estimating germline maintenance. by Mareike Koppik (4489318)

Table1_The real-world analysis of adverse events with teduglutide: a pharmacovigilance study based on the FAERS database.pdf by Xiaogan Wang (4978514)

Table1_A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.... by Huanying Xu (17813399)

Supplementary Material for: First-in-human effects of PPT1 inhibition using the oral treatment with GNS561/ Ezurpimtrostat in patients with primary and secondary liver cancers by Harding J.J. (12088145)

A Meta-Analysis of Anti-Vascular Endothelial Growth Factor Remedy for Macular Edema Secondary to Central Retinal Vein Occlusion by Peirong Huang (501361)

“…Primary outcomes showed that overall comparison of anti-VEGF agents with placebo control yielded a 374% and 136% increased tendency for a gain of 15 letters or more on Early Treatment Diabetic Retinopathy Study (ETDRS) chart (95% confidence interval [95% CI]: 2.43–9.23; P<0.00001; <i>I²</i> = 59%, 95% CI: 1.60–3.49; P<0.0001; <i>I²</i> = 0%, respectively) at 6 and 12 months. …”